Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Einfluss des regelmäßigen Verzehrs von Eiern und mit Nährstoffen angereicherten Eiern auf den Ekzemzustand bei Personen in Singapur

10. November 2026 aktualisiert von: Jung Eun Kim, National University of Singapore

Einfluss des regelmäßigen Verzehrs von Eiern und mit Nährstoffen angereicherten Eiern auf den Ekzemzustand bei Personen mit Ekzemen in Singapur

The study aims to assess the effects of daily consumption of nutrients-fortified eggs on eczema condition in Singapore individuals with eczema. The investigators hypothesize that egg consumption will improve eczema condition and nutrients fortified egg consumption will improve further improvements when compared to standard egg consumption in individuals with eczema

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This is a double-blind, randomized, parallel study and all subjects will complete a 12-week study period. Subjects will be tasked to consume nutrients-fortified eggs and regular eggs daily for 12 weeks. After which, subjects are assessed for changes in carotenoid status, antioxidant and anti-inflammatory biomarkers, skin and eye health measurements, and other biomarkers of health.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

43

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Singapore
      • Singapore, Singapore, Singapur, 117550
        • Department of Food Science and Techonology, Block S13

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

21 Jahre bis 59 Jahre (Erwachsene)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. English-literate and able to give informed consent in English
  2. Male and female participants, aged between 21 and 59 inclusive
  3. Healthy individuals with no underlying condition or on regular medication
  4. BMI between 18.5-25 kg/m2
  5. Mild to moderate severity of eczema, which will also be determined using our questionnaires during the screening visit

Exclusion Criteria:

  1. Significant change in body weight (3 kg or more) in the past 3 months
  2. Significant exercise pattern over the past 3 months defined as high-intensity exercise of more than 3 hours per week
  3. Known food allergy to eggs
  4. Taking dietary supplements which may impact the study results
  5. Having gastrointestinal disorders not suitable for the study
  6. Current smokers
  7. Consumes more than 2 alcoholic drinks per day i.e. one drink is defined as either 150ml of wine, 340ml of beer/cider, or 45ml of distilled spirit
  8. Taking lipid-lowering and blood pressure-controlling medications for less than 3 years
  9. Pregnant or lactating women, or planning to conceive in the next 6 months
  10. Unwilling to stop the medication of eczema during the study, either topical creams or oral medications
  11. Hierarchical link (professional and familial ties) with the research team members
  12. Participating in another clinical study
  13. Having blindness in one eye or more, eye diseases, retinal/lens/optical nerve surgery, or other eye conditions that may impact the study results
  14. Low-quality macular pigment optical density results were determined during the screening visit.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Regular egg with habitual diet

Each subject will be provide one-on-one dietary counselling and written instructions for each subject will be provided by a research dietitian and trained research staff.Subjects will also be provided with 2 regular egg/day for 12 weeks.

Consumption of regular egg with habitual diet

Experimental: Nutrient-fortified egg with habitual diet

Each subject will be provide one-on-one dietary counselling and written instructions for each subject will be provided by a research dietitian and trained research staff.Subjects will also be provided with 2 nutrient-fortified egg/day for 12 weeks.

Consumption of nutrient-fortified eggs with habitual diet

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Skin questionnaires - SCORing Atopic Dermatitis (SCORAD) Index
Zeitfenster: Week 0, week 3, week 6, week 9, week 12

SCORing Atopic Dermatitis (SCORAD) Index is a clinical tool used to assess the severity of atopic dermatitis (AD), also known as eczema. This index can estimate participants' body surface area affected by burns (extent - A: percentage of body surface area affected), Intensity (B: clinical signs are assessed and scored on a scale from 0 (absent) to 3 (severe)), Subjective Symptoms (C: itch, sleep disturbance are evaluated based on the participants' report over the past three days, each scored on a scale from 0 (no symptom) to 10(severe symptom)).

The SCORAD index is calculated using the following formula:

SCORAD=A/5+7B/2+C

Interpretation Mild atopic dermatitis: SCORAD < 25 Moderate atopic dermatitis: SCORAD 25-50 Severe atopic dermatitis: SCORAD > 50

Week 0, week 3, week 6, week 9, week 12
Skin questionnaires - Eczema Area and Severity Index (EASI) scoring system
Zeitfenster: Week 0, week 3, week 6, week 9, week 12

EASI evaluates the extent and severity of eczema in four body regions: the head and neck, the trunk, the upper limbs, and the lower limbs.

The EASI score ranges from 0 to 72, with higher scores indicating more severe eczema:

0: No eczema 1-7: Mild eczema 8-21: Moderate eczema 22-50: Severe eczema 51-72: Very severe eczema

Week 0, week 3, week 6, week 9, week 12
Skin questionnaires - Dermatology life quality index (DLQI)
Zeitfenster: Week 0, week 3, week 6, week 9, week 12

DLQI is a dermatology-specific instrument used to measure the impact of skin diseases on patients' quality of life. Which assessed disease impact, monitor treatment effectiveness, guide clinical decision-making.

Interpretation of Scores:

0-1: No effect on patient's life 2-5: Small effect on patient's life 6-10: Moderate effect on patient's life 11-20: Very large effect on patient's life 21-30: Extremely large effect on patient's life

Week 0, week 3, week 6, week 9, week 12
Skin measurement - eczema related
Zeitfenster: Week 0, week 3, week 6, week 9, week 12

Skin hydration - units arbitrary Corneometer®. Transepidermal water loss - units gram/hour. Sebum level - unit µg/cm2. Skin pH level - skin pH meter. Skin tape stripping: stratum corneum components assessed by immune dot blots

Week 0, week 3, week 6, week 9, week 12
Skin carotenoids status
Zeitfenster: Week 0, week 3, week 6, week 9, week 12

Skin carotenoids concentration can be measured by Resonance Raman Spectroscopy, unit is skin carotenoid score, higher score means optimal, lower score means poor condition of skin carotenoids.

Week 0, week 3, week 6, week 9, week 12
Blood carotenoids levels
Zeitfenster: Week 0, week 6, week 12

Blood carotenoids levels can be measured by High-Performance Liquid Chromatography, unit is μmol/L.

Week 0, week 6, week 12

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Eye health - Macular Pigment Optical Density
Zeitfenster: Week 0, week 3, week 6, week 9, week 12

A measurement of macular pigment of the eye using a heterochromatic flicker photometry device. The measurements are in arbitrary units.

Week 0, week 3, week 6, week 9, week 12
Eye health - Visual acuity
Zeitfenster: Week 0, week 3, week 6, week 9, week 12

Participants will read out letters on a ETDRS LogMAR chart at a fixed distance where letters becomes smaller as it goes down the chart. Tests results will be recorded in number of letters read, where the more letters the better the outcome.

Week 0, week 3, week 6, week 9, week 12
Eye health - Photostress recovery time
Zeitfenster: Week 0, week 3, week 6, week 9, week 12

An ophthalmoscope will be used to shine a light into the participants eye for 10 seconds, and participants will be required to read letters off a chart the moment their vision returns to normal. The faster the recovery time, the better the outcome. Units will be in seconds

Week 0, week 3, week 6, week 9, week 12
Visual function questionnaire 25
Zeitfenster: Week 0, week 3, week 6, week 9, week 12

A questionnaire to for participants to self-evaluate their perception of their current eye health based on general vision, ocular pain, near activities, distance activities, vision specific functions, driving, color vision and peripheral vision. The best possible score is 100 and worst possible score is 0.

Week 0, week 3, week 6, week 9, week 12
Concentration of tumour necrosis factor-α
Zeitfenster: Week 0, week 6, week 12

The blood obtained from the participants will be processed for storage. Tumor necrosis factor-α results will be presented in ng/L according to the commercially available enzyme-linked immunosorbent assay kits.

Week 0, week 6, week 12
Concentration of interleukin-6
Zeitfenster: Week 0, week 6, week 12

The blood obtained from the participants will be processed for storage. Interleukin-6 results will be presented in ng/L according to the commercially available enzyme-linked immunosorbent assay kits.

Week 0, week 6, week 12
Concentration of high-sensitivity C-reactive protein
Zeitfenster: Week 0, week 6, week 12

The blood obtained from the participants will be processed for storage. High-sensitivity C-reactive protein results will be obtained and presented in mg/L by commercial lab testing.

Week 0, week 6, week 12
Concentration of fasting blood glucose
Zeitfenster: Week 0, week 6, week 12

Fasting blood glucose will be measured using commercial lab testing using participants' blood, units will be in mmol/L.

Week 0, week 6, week 12
Concentration of malondialdehyde
Zeitfenster: Week 0, week 6, week 12

The blood obtained from the participants will be processed for storage. Analyses of malondialdehyde using commercially available enzyme-linked immunosorbent assay kits. Units for malondialdehyde will be in ng/L according to assay kit instructions.

Week 0, week 6, week 12
Concentration of 8-isoprostaglandin-F2α
Zeitfenster: Week 0, week 6, week 12

The blood obtained from the participants will be processed for storage. Analyses of 8-isoprostaglandin-F2α using commercially available enzyme-linked immunosorbent assay kits. Units for 8-isoprostaglandin-F2α will be in µmol/L according to assay kit instructions.

Week 0, week 6, week 12
Concentration of insulin
Zeitfenster: Week 0, week 6, week 12

Fasting blood insulin will be measured using commercial lab testing using participants' blood, units in μU/L.

Week 0, week 6, week 12
Percentage of glycated hemoglobin
Zeitfenster: Week 0, week 6, week 12

Glycated hemoglobin will be measured using commercial lab testing from participant's blood, units in percent.

Week 0, week 6, week 12
Skin advanced glycation end products levels
Zeitfenster: Week 0, week 3, week 6, week 9, week 12

Measurement of skin advanced glycation end products level using a skin autofluorescence device, where participants wlll be instructed to place their forearm over the device and a light will be shone and a reading can be captured by detecting fluorescence. The results will be presented as arbitrary units.

Week 0, week 3, week 6, week 9, week 12
Blood advanced glycation end products levels
Zeitfenster: Week 0, week 3, week 6, week 9, week 12

Participants will have their blood drawn by medical professionals at the Occupational Health Clinic. The blood will be processed and stored. Measurements will be done using ultra-performance liquid chromatography coupled with mass spectrometry techniques to determine the levels of advanced glycation end products. Units will be in μg/mL.

Week 0, week 3, week 6, week 9, week 12

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Dietary assessment
Zeitfenster: Week 0, week 3, week 6, week 9, week 12

3-day food record will be used to assess participants' dietary intake for two weekdays and one weekend day before each clinical visit.

Week 0, week 3, week 6, week 9, week 12
Measurement of height
Zeitfenster: Week 0, week 3, week 6, week 9, week 12

Height will be measured using height-weight scale and units will be in cm.

Week 0, week 3, week 6, week 9, week 12
Measurement of blood pressure
Zeitfenster: Week 0, week 3, week 6, week 9, week 12

A blood pressure monitoring device available commercially will be used be to measure their systolic and diastolic blood pressure. Unit is mmHg.

Week 0, week 3, week 6, week 9, week 12
Measurement of weight
Zeitfenster: Week 0, week 3, week 6, week 9, week 12

Weight will be measured using height-weight scale and units will be in kg.

Week 0, week 3, week 6, week 9, week 12
Measurement of waist circumference
Zeitfenster: Week 0, week 3, week 6, week 9, week 12

Waist circumference will be measured using a measuring tape by a trained personnel, units in cm.

Week 0, week 3, week 6, week 9, week 12

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Hauptermittler: Jung Eun Kim, PhD, RD, National University of Singapore

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

17. Juli 2024

Primärer Abschluss (Tatsächlich)

27. Oktober 2025

Studienabschluss (Tatsächlich)

1. Dezember 2025

Studienanmeldedaten

Zuerst eingereicht

7. April 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

10. Juni 2024

Zuerst gepostet (Tatsächlich)

12. Juni 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

16. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

10. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • S26

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

The link between participants' information data and the code will be kept confidential by the NUS research team or a trusted third party. Research data and results will only be collated in its coded format. All research data collected will be retained for a minimum of 10 years following the NUS Research Data Management Policy.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .